ALX Oncology Inc.
South San Francisco, CA, USA
ALX Oncology is a clinical-stage and patient-focused immuno-oncology company developing therapies that block the CD47 myeloid checkpoint pathway. Our lead candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. For more information about us, please visit www.alxoncology.com. POSITION SUMMARY: Reporting to the Chief Medical Officer, the Vice President, Biometrics will be responsible for overseeing all aspects of biometrics, including statistical analysis, data management, and programming, to support the design, analysis, and reporting of clinical trials. This role requires a strategic thinker with deep expertise in biometrics, a strong understanding of regulatory requirements, and the ability to collaborate cross-functionally to drive clinical development programs forward. The ideal candidate will have a proven track record of leading biometrics teams in the...